Assess Therapeutic Efficacy and Emergence of HIV Drug Resistance Following Initiation of TLD

CompletedOBSERVATIONAL
Enrollment

1,339

Participants

Timeline

Start Date

October 28, 2019

Primary Completion Date

March 31, 2023

Study Completion Date

March 31, 2023

Conditions
HIV-1-infection
Trial Locations (14)

2193

University of the Witwatersrand Helen Joseph (WITS HJH) CRS (11101), Johannesburg

7505

Family Clinical Research Unit (FAM-CUR) CRS (8950), Cape Town

7705

University of Cape Town Lung Institute (UCTLI) CRS (31792), Cape Town

20200

Kenya Medical Research Institute/Walter Reed Project Clinical Research Center (KEMRI/WRP) CRS (12501), Kericho

30100

Moi University Clinical Research Center (MUCRC) CRS (12601), Eldoret

40100

Kisumu Crs (31460), Kisumu

HT-6110

Les Centres GHESKIO CRS (30022), Port-au-Prince

Unknown

GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS (31730), Port-au-Prince

Blantyre CRS (30301), Blantyre

Malawi CRS (12001), Lilongwe

Soweto ACTG CRS (12301), Johannesburg

Joint Clinical Research Centre (JCRC)/Kampala CRS (12401), Kampala

Milton Park CRS (30313), Harare

4013 SF

Durban Adult HIV CRS (11201), Durban

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

United States President's Emergency Plan for AIDS Relief

FED

lead

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NETWORK

NCT04050449 - Assess Therapeutic Efficacy and Emergence of HIV Drug Resistance Following Initiation of TLD | Biotech Hunter | Biotech Hunter